Core Viewpoint - Morgan Stanley expects that the new drug tariff policy will not have a direct impact on Chinese CDMO companies like WuXi AppTec, as clients typically bear the tariff costs, and WuXi AppTec is expanding its production capacity in the U.S. to meet local production demands [1] Group 1: Company Analysis - WuXi AppTec is identified as the largest contract research and manufacturing organization in China, with strong business fundamentals [1] - The competition in the small molecule CRDMO sector is considered relatively mild, which bodes well for WuXi AppTec's market position [1] - The growth momentum of WuXi AppTec's TIDES business remains robust, indicating a positive outlook for the company's future performance [1] Group 2: Market Outlook - Morgan Stanley maintains an "Overweight" rating on WuXi AppTec, with a target price set at HKD 138 [1] - The report follows the announcement by former President Trump regarding a 100% tariff on imported brand-name and patented drugs starting October 1, unless related manufacturers have begun construction of production facilities in the U.S. [1]

Core Viewpoint - Morgan Stanley continues to favor WuXi AppTec (02359) as the top pick in China's CXO industry, highlighting its position as the largest contract research and manufacturing organization in China and expressing optimism about its business fundamentals [1] Group 1: Company Performance - WuXi AppTec is recognized as the largest contract research and development organization in China, indicating strong market presence [1] - The competition in the small molecule CRDMO sector is relatively mild, suggesting a favorable operating environment for WuXi AppTec [1] - The growth momentum in WuXi TIDES business remains robust, contributing positively to the company's outlook [1] Group 2: Market Impact - Morgan Stanley maintains an "overweight" rating for WuXi AppTec with a target price of HKD 138 [1] - The recent announcement by former President Trump regarding a 100% tariff on imported brand-name and patented drugs starting October 1 is not expected to directly impact WuXi AppTec and similar Chinese CDMO companies, as clients typically bear the tariff costs [1] - WuXi AppTec is expanding its production capacity in the U.S. to meet client demands for localized production, which may mitigate potential impacts from the tariff policy [1]

Core Viewpoint - Morgan Stanley's research report indicates that the recent announcement by U.S. President Trump to impose a 100% tariff on imported branded and patented drugs starting October 1 will not directly impact Chinese CDMO companies like WuXi AppTec, as clients typically bear the tariff costs [1] Group 1: Company Analysis - WuXi AppTec is recognized as the largest contract research and manufacturing organization in China, with strong business fundamentals [1] - The company is expanding its production capacity in the U.S. to meet client demands for localized manufacturing [1] - Morgan Stanley maintains an "Overweight" rating on WuXi AppTec, with a target price of HKD 138 [1] Group 2: Industry Insights - The competition in the small molecule CRDMO sector is relatively mild, which bodes well for WuXi AppTec's growth prospects [1] - The growth momentum for WuXi TIDES business remains strong, indicating a positive outlook for the company's future performance [1]